Can You Preserve Muscle While Taking Wegovy or Zepbound?

Can I lose muscle while taking Wegovy or Zepbound?

Yes, studies found reductions in lean body mass during treatment, though those measurements do not tell exactly how much skeletal muscle or strength each person lost. That distinction matters: a change in a body-composition scan is not a direct assessment of how well someone can stand, climb stairs, or lift an object.

In a 2021 analysis of a DXA substudy, Wilding and colleagues reported that participants taking semaglutide lost an average of 15.0% of body weight over 68 weeks. Fat mass fell 19.3%, and total lean body mass fell 9.7%. Lean mass as a share of total body mass rose by 3 percentage points. The substudy included 140 participants, 95 of whom received semaglutide, and its small size and measurement method limit what it can say about individual muscle or strength changes. The STEP 1 body-composition analysis shows why weight and body composition are related, but not interchangeable.

A 2025 analysis by Look and colleagues examined DXA results from 160 participants in SURMOUNT-1: 124 received tirzepatide and 36 received placebo. At 72 weeks, the tirzepatide group had mean reductions of 21.3% in body weight, 33.9% in fat mass, and 10.9% in lean mass. The authors estimated that roughly 74% of lost weight was fat and 26% lean mass. As with the semaglutide analysis, DXA lean mass is not a direct muscle-strength test. The SURMOUNT-1 analysis offers a group-level picture, not a prediction for one person.

The practical point is not to treat every change in lean mass as proof of muscle loss. It is to pair weight-related measures with real-world function. Tell the care team about a sustained drop in strength, difficulty with usual daily tasks, worsening ability to get up from a chair, or trouble maintaining food and fluid intake. These changes merit a conversation about the treatment and nutrition plan.

What exercises help preserve muscle on a GLP-1 medication?

Resistance exercises are the main activity to discuss for preserving lean body mass during weight loss. A 2025 multidisciplinary expert consensus recommends individualized exercise and resistance training, while noting that direct evidence for lifestyle interventions alongside GLP-1-based medicines remains limited.

A beginner-friendly framework is to choose a few movements that train major muscle groups, then build the effort gradually. Options named in a 2025 JAMA Internal Medicine article include resistance bands, weights, and body-weight movements. The exact exercises and starting effort depend on a person’s health, experience, balance, joint symptoms, and clinician’s guidance.

For someone returning after inactivity, small, manageable amounts provide a starting point. The U.S. Department of Health and Human Services’ Physical Activity Guidelines recommend adults do muscle-strengthening activity on at least 2 days each week, alongside 150–300 minutes of moderate-intensity aerobic activity weekly for substantial health benefits. The federal guidance also says inactive people should begin with small amounts and build gradually. These are general adult guidelines, not a prescription specific to Wegovy or Zepbound.

Strength is one useful signal to track. Notice whether a familiar movement becomes harder, whether everyday tasks take more effort, or whether training feels persistently less manageable. Share those changes with the care team rather than pushing through a decline. The pace and type of training can be adjusted to fit an individual’s health and current capacity.

How often should I strength train while taking semaglutide?

There is no single medication-specific schedule in the supplied sources. Federal guidelines recommend muscle-strengthening activity at least 2 days a week for adults, and a 2025 JAMA Internal Medicine article describes gradually building toward strength training 2–3 times weekly. A clinician can help determine a suitable frequency and starting point.

The difference between those figures reflects their purpose: the federal recommendation is a broad adult activity guideline, while the article offers beginner-oriented advice in the context of GLP-1-based weight-loss treatment. Neither establishes the best schedule for every person taking semaglutide. Health conditions, current fitness, recovery, and the ability to eat and drink enough all affect the discussion.

A sensible conversation with the care team can cover which movements are appropriate, how to start at a manageable level, and what signs mean the plan needs review. If strength or daily function declines, or gastrointestinal symptoms interfere with eating and drinking, report that rather than assuming weight loss alone explains it. The 2025 expert consensus specifically calls for monitoring nutrition, hydration, excessive weight loss, and gastrointestinal symptoms.

Protein is part of the same plan, not a substitute for strength training. The 2025 consensus says protein recommendations should be tailored and cautions that high protein intake alone does not increase muscle mass. Reduced appetite can make meals smaller, so meal timing and food choices are worth discussing alongside exercise.